North America’s medical devices industry saw a drop of 11.40% in deal activity during September 2022, when compared with the last 12-month average, led by CVS Health’s $8bn acquisition of Signify Health, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 101 medical devices industry deals worth $10.3bn were announced for the region in September 2022, against the 12-month average of 114 deals.
Of all the deal types, venture financing saw most activity in September 2022 with 76 transactions, representing a 75.3% share for the region.
In second place was M&A with 20 deals, followed by private equity deals with five transactions, respectively capturing a 19.8% and 5% share of the overall deal activity for the month.
In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $9.07bn, while venture financing and private equity deals totalled $764.61m and $488m, respectively.
North America medical devices industry deals in September 2022: Top deals
The top five medical devices deals accounted for 91.5% of the overall value during September 2022.
The combined value of the top five medical devices deals stood at $9.44bn, against the overall value of $10.3bn recorded for the month.
The top five medical devices industry deals of September 2022 tracked by GlobalData were:
1) CVS Health’s $8bn acquisition deal with Signify Health
2) The $875m acquisition of Rx Savings Solutions by McKesson
3) Orbimed Advisors’s $250m private equity deal with Adaptive Biotechnologies
4) The $165m private equity of Theragun by HartBeat Ventures, North Castle Partners and Rx3 Ventures
5) Halma’s $154.02m acquisition deal with IZI Medical Products
